ArticleCurrent treatment options in cardiovascular medicine2014
Pluripotent stem cell derived cardiomyocytes for cardiac repair.
Article in Current treatment options in cardiovascular medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Engineering Functional Cardiac Tissues for Regenerative Medicine Applications.Current cardiology reports · 2019Pooled it
- Evolving Strategies for Extracellular Vesicles as Future Cardiac Therapeutics: From Macro- to Nano-Applications.International journal of molecular sciences · 2024Review
- Ameliorating impaired cardiac function in myocardial infarction using exosome-loaded gallic-acid-containing polyurethane scaffolds.Bioactive materials · 2024Article
- Therapeutic Potential of Extracellular Vesicles from Different Stem Cells in Chronic Wound Healing.Stem cell reviews and reports · 2023Review
- Nanotechnology in interventional cardiology: A state-of-the-art review.International journal of cardiology. Heart & vasculature · 2022Review
- Latest Advances in 3D Bioprinting of Cardiac Tissues.Advanced materials technologies · 2022Article
- A Roadmap to Cardiac Tissue-Engineered Construct Preservation: Insights from Cells, Tissues, and Organs.Advanced materials (Deerfield Beach, Fla.) · 2021Review
- Mechanical stimulation enhances development of scaffold-free, 3D-printed, engineered heart tissue grafts.Journal of tissue engineering and regenerative medicine · 2021Article
- Preseeding of Mesenchymal Stem Cells Increases Integration of an iPSC-Derived CM Sheet into a Cardiac Matrix.ACS biomaterials science & engineering · 2020Article
- Human iPS cell-derived engineered heart tissue does not affect ventricular arrhythmias in a guinea pig cryo-injury model.Scientific reports · 2019Article
- A Net Mold-Based Method of Biomaterial-Free Three-Dimensional Cardiac Tissue Creation.Tissue engineering. Part C, Methods · 2019Article
- Toward Regeneration of the Heart: Bioengineering Strategies for Immunomodulation.Frontiers in cardiovascular medicine · 2019Review
- Cell therapy trials for heart regeneration - lessons learned and future directions.Nature reviews. Cardiology · 2018Review
- 3D bioprinting of functional tissue models for personalized drug screening and in vitro disease modeling.Advanced drug delivery reviews · 2018Review
- Effective Hypothermic Storage of Human Pluripotent Stem Cell-Derived Cardiomyocytes Compatible With Global Distribution of Cells for Clinical Applications and Toxicology Testing.Stem cells translational medicine · 2016Article
- Expansion and patterning of cardiovascular progenitors derived from human pluripotent stem cells.Nature biotechnology · 2015Article
- New model for cardiomyocyte sheet transplantation using a virus-cell fusion technique.World journal of stem cells · 2015Article
- Perspectives of induced pluripotent stem cells for cardiovascular system regeneration.Experimental biology and medicine (Maywood, N.J.) · 2015Review
- Making it stick: chasing the optimal stem cells for cardiac regeneration.Expert review of cardiovascular therapy · 2014Review
- The potential and challenges of using stem cells for cardiovascular repair and regeneration.Genes & diseases · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
opinion statementThe adult mammalian heart has limited capacity for regeneration, and any major injury such as a myocardial infarction results in the permanent loss of up to 1 billion cardiomyocytes. The field of cardiac cell therapy aims to replace these lost contractile units with de novo cardiomyocytes to restore lost systolic function and prevent progression to heart failure. Arguably, the ideal cell for this application is the human cardiomyocyte itself, which can electromechanically couple with host myocardium and contribute active systolic force. Pluripotent stem cells from human embryonic or induced pluripotent lineages are attractive sources for cardiomyocytes, and preclinical investigation of these cells is in progress. Recent work has focused on the efficient generation and purification of cardiomyocytes, tissue engineering efforts, and examining the consequences of cell transplantation from mechanical, vascular, and electrical standpoints. Here we discuss historical and contemporary aspects of pluripotent stem cell-based cardiac cell therapy, with an emphasis on recent preclinical studies with translational goals.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.